PMVP 8-K: SEC filing
PMV Pharmaceuticals
Filed with the SEC on · accession 0001193125-26-470247
PMVP filed a 8-K (current report) with the SEC on Nov 20, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The stock moved -33.1% by the first close after the filing.
Summary of the filing
PMV Pharmaceuticals announced updated data from the Phase 2 pivotal portion of the PYNNACLE clinical trial of rezatapopt via a press release furnished on Form 8-K.
Key details
How PMVP stock reacted
Close before
$1.31
Nov 19, 2026
First close after
-33.13%
$0.88
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for PMVP, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for PMVP?
Click hereFrequently asked questions
What did PMVP file with the SEC on Nov 20, 2026?
PMVP filed a 8-K (SEC filing). PMV Pharmaceuticals announced updated data from the Phase 2 pivotal portion of the PYNNACLE clinical trial of rezatapopt via a press release furnished on Form 8-K.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
How did PMVP stock react to this filing?
PMVP closed at $1.31 before the filing and $0.88 on Nov 20, 2026 (-33.13%).
Other PMVP SEC filings
- SCHEDULE 13G/A · SEC filingNov 16, 2026
- 10-Q · SEC filingNov 10, 2026
- 8-K · SEC filingNov 10, 2026
- 8-K · Board changeOct 5, 2026
- 8-K · Secondary offeringSep 2, 2026
- 424B5 · Secondary offeringSep 2, 2026
- 8-K · Fda approvalAug 31, 2026
- 424B5 · Secondary offeringAug 31, 2026
- 424B3 · Secondary offeringAug 31, 2026
- 10-Q · SEC filingAug 14, 2026
Get alerts when PMVP files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days